<?xml version="1.0" encoding="UTF-8"?>
<fig id="f3-1030522" position="float">
 <label>Figure 3.</label>
 <caption>
  <p>cGvHD: survival and GRFS outcomes. Cumulative incidence of (A) all cGvHD, and Kaplan-Meier survival plots of (B) progression-free survival (PFS), (C) overall survival (OS), and (D) grade III-IV aGvHD/cGvHD requiring systemic IS agents/relapse-free survival (GRFS) per treatment arm. Black indicates arm A (tac/mtx), red indicates arm B (bort/tac/mtx), and blue indicates arm C (bort/sir/tac). Tac: tacrolimus; Mtx: methotrexate; Bort: bortezomib; Sir: sirolimus; GvHD: graft-
   <italic>versus</italic>-host disease.
  </p>
 </caption>
 <graphic xlink:href="103522.fig3" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
